EGFR and non-small cell lung carcinoma: A pooled analysis including 464 patients from 16 trials to study the efficacy of first generation EGFR-TKIs (gefitinib, erlotinib) in NSCLC patients with BM showed significant beneficial effects, with a higher response rate (85 vs 45.1%) for EGFR mutated vs wild-type tumors and a median PFS of 7.4 months, and OS of 11.9 months in the EGFR mutation group (186).